Shiseido Develops Next-generation Mascara Technology “WASHABLE LOCK TECHNOLOGY™” - 資生堂 企業情報
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
This article is an excerpt. To read the full content, visit the original source. 資生堂 企業情報
Related articles

ChatGPT now lets you lock your chats - TechCrunch
OpenAI announced on Tuesday that users can now lock ChatGPT conversations to keep sensitive chats private when others may have access to their screen or device. Users can secure their locked chats with a four-digit PIN, or use Face ID or Touch ID on supported devices. Unlike the app’s Temporary Chats, which provide a separate session that doesn’t appear in chat history, users can return to Locked Chats at any time.

$50 Million Bra, $25 Mascara—Every Product Kylie Jenner Wore on Her First Victoria’s Secret Runway - Who What Wear
I can already see the endless recreations.

Investigational FXI Monoclonal Antibodies Show Early Promise for Thrombosis - DocWireNews
The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.

Gemini's Personal Intelligence is coming to cars - Ars Technica
Google kicked off 2026 with the addition of Personal Intelligence to Gemini, allowing its AI to pull in more of your data to formulate answers. It started as a paid feature but eventually came to all Gemini users. However, this feature wasn’t available in the car until now. Google is rolling out Personal Intelligence to Android Auto and Google Built-in, and it is still, thankfully, an optional feature. As Google points out, a generative AI’s outputs are better “when it knows the world and knows you,” which is correct in an uncomfortable sort of way. The more context you can provide to a model, the better the output will be at the end of the token shuffle. Since Google has so much of your data already, it sees Personal Intelligence as a differentiator versus other AI systems. You don’t have to provide the AI context because it already has it from apps like Gmail and Calendar.
0 comments
No comments yet. Be the first to share your thoughts!